AACO

The I5T-MC-AACO/TRAILBLAZER-ALZ 5 study will evaluate the efficacy and safety of donanemab, a monoclonal antibody targeting beta-amyloid protein, in people with early-stage Alzheimer's disease.

The BBRC is one of the centers participating in this international clinical trial led by the pharmaceutical company Lilly. Participants will undergo the tests established in the study protocol, such as cognitive assessments and neuroimaging tests, and will be administered the investigational treatment or placebo, provided they meet all the inclusion criteria for this phase III clinical trial.